Skip to main content

Table 2 Assessments administered during each phase of Insight 46

From: Updating the study protocol: Insight 46 – a longitudinal neuroscience sub-study of the MRC National Survey of Health and Development – phases 2 and 3

Assessment

References

Phase 1

Phase 2

Phase 3

Clinic

Remote – computer

Remote - telephone

Neuropsychological Assessments

 12-Item Face—Name Associative Memory Exam (FNAME)

[10, 18, 21]

(version A)

a (version A)

a (version A)

a (version B)

 15-Item Word List Learning Task

[11, 22]

a

 Adult Memory and Information Processing Battery (AMIPB) Complex Figure

[23]

a (AMIPB figure version 1)

a (AMIPB figure version 1)

a (AMIPB figure version 2)

 Choice Reaction Time/Response Inhibition

[10, 19]

(inhibition condition removed, choice reaction time still administered)

 Graded Naming Test (GNT)

[24]

 Instructionless Eye Tracking

[25]

(first administered in Feb 2017)

 Irrelevant Distractor Task

[10]

 Visual Search Speed Task

[11, 22]

 Visual Short-term Memory Binding

[10, 26]

 Visuomotor Integration Circle-Tracing Task with Concurrent (Dual-Task) Serial Subtraction

[10, 27]

(plus single-task circle tracing and single-task serial subtraction)

 Wechsler Abbreviated Scale of Intelligence (WASI) – Matrix Reasoning

[10, 18]

 Wechsler Adult Intelligence Scale-Revised (WAIS-R) – Digit-Symbol Substitution Test (DSST)

[10, 18]

 Wechsler Memory Scale – Revised (WMS-R) Logical Memory Recall IIa (Immediate and Delayed)

[10, 18]

 Wechsler Memory Scale (WMS) Digit Span Forward and Backward

[28]

Digital Technologies Used During Neuropsychological Assessments

 Anoto AP-701 Digital Pen

[29]

(DSST, AMIPB complex figure, MMSE)

 Audio Recordings

[30]

(GNT)

(GNT)

(GNT, WMS-R Logical Memory Recall IIa Immediate and Delayed, Serial Subtraction)

 Empatica

 

Memory and Clinical Interviews

 AD8 Dementia Screening Interview

[10, 31,32,33]

 Clinical Dementia Rating (CDR) Scale

[34, 35]

 Delirium Questionnaire

 

 History of Neurological Diagnosis (Personal and Family)

[10, 33]

 Mini Mental State Examination (MMSE)

[10, 18, 36]

 MyCog

[10, 33]

 Subjective Cognitive Decline Questions

[10, 33]

Physical Assessments

 Blood Pressure

[10, 37, 38]

(lying, standing)

(sitting, lying, standing)

(sitting, lying, standing)

 Bradykinesia Akinesia Incoordination (BRAIN) Tap Test

[10]

 Self-paced Gait in Isolation and with Cognitive Task

[10]

 Walking Speed

[39]

 Height

[10, 11]

 Weight

[10, 11]

(estimated)

(estimated)

 Hip and Waist Circumference

[11, 40]

 Bioimpedance

 

 Unified Parkinson’s Disease Rating Scale (UPDRS) – Part III: Motor Examination

[10]

(partial)

 6-Minute Stepper Test

[13, 41]

 Grip Strength

[11, 42]

 Chair Rises

[11, 43]

 Standing and Walking Balance

[11, 44]

 Spirometry

[45, 46]

Home Wearables

 Actigraphy

 

 Glucose Monitor

[47]

Sensory

 Pure Tone Audiometry

[10, 48]

 Word in Noise

[10]

 University of Pennsylvania Smell Identification Test (UPSIT)

[10, 49]

 Portable Eye Examination Kit (PEEK)

[10]

 Spoons Taste Test

[50]

Self-Complete Questionnaires

 Dental Hygiene

[10]

 Handedness

[10]

 State-Trait Anxiety Inventory (STAI)

[10, 33]

 Question About Movement in Sleep

[10]

 Epworth Sleepiness Scale (ESS)

[51, 52]

 Pittsburgh Sleep Quality Index (PSQI)

[53]

 REM Sleep Behaviour Disorder Questionnaire (RSBDQ)

[54]

 Perseverative Thinking Questionnaire (PTQ)

[55]

 Head Injury Questionnaire

[56]

 General Health Questionnaire (GHQ)-28

[11, 57, 58]

Biofluid Sampling

 Blood – Haematology and Biochemistry

[59]

 Blood – DNA

 

 Blood – RNA

 

 Blood – Cell Lines

[60, 61]

 Blood – Biomarkers

[16, 62]

 Urine – Biomarkers

 

 Urine – Spot Urine Sample

[11]

 Cerebrospinal Fluid

[62]

Cardiovascular Measurements

 2D and 3D Echocardiography

[11, 13]

 Carotid Intima-Media Thickness

[11, 13]

 Carotid Femoral Pulse Wave Velocity (PWV)

[11, 13]

 Pulse Wave Analysis (PWA) – Central Blood Pressure

[11, 13]

 Electrocardiogram (ECG)

[11, 13]

 Functional Near-Infrared Spectroscopy (fNIRS)

[13]

Imaging

 Positron Emission Tomography (PET)

[63]

[18F]florbetapir (Aβ)

[18F]florbetapir (Aβ)

[18F]florbetaben (Aβ) or [18F]MK6240 (tau)

 Brain Magnetic Resonance Imaging (MRI)

[63, 64]

 Dual-energy X-ray Absorptiometry (DXA)

[11, 40]

 Optical Coherence Tomography (OCT)

 

  1. aThese assessments were part of an accelerated-forgetting paradigm that involved calling participants seven days after their research visit to ask follow-up questions